Navigation Links
HPV Tied to Better Tongue, Tonsil Cancer Outcomes
Date:5/14/2008

Patients more likely to survive using chemoradiation, and new treatments may follow

WEDNESDAY, May 14 (HealthDay News) -- Tonsil and tongue cancers linked to human papillomavirus (HPV) are most responsive to current chemotherapy and radiation treatments, while those that express high levels of a growth factor called EGFR are the least responsive and most deadly, a new study concludes.

University of Michigan Comprehensive Cancer Center researchers identified a series of markers that identify which patients are most likely to survive these types of cancers. The findings are a promising step toward the development of individualized treatments for tonsil and tongue cancers, according to the authors of two papers published online May 12 in the Journal of Clinical Oncology and expected to be in the July 1 print issue.

"The chemotherapy and radiation therapy we use to treat this type of cancer is very aggressive. If we can identify those patients most likely to respond, we could reduce the intensity of the therapy for those likely to have the best outcomes. At the same time, we hope to identify new treatments that specifically target those tumors that we know are not responding to current therapies," Thomas Carey, co-director of the head and neck oncology program at the U-M Comprehensive Cancer Center, said in a prepared statement. He was the senior author on both papers.

The researchers gave an initial course of chemotherapy to 66 people with advanced oropharyngeal cancer, which includes cancer of the tonsils and the base of the tongue. Patients (54) who responded to this initial treatment then received a full course of simultaneous chemotherapy and radiation. Patients (11) who didn't respond to the initial chemotherapy were referred for surgery.

Of the 54 patients who responded to the initial chemotherapy, 62 percent are alive today without evidence of cancer, and 73 percent fully preserved their organs. Of the 11 patients referred for surgery, only four survived.

"For most patients, the chemoradiation was very effective. But a subset of patients still do not do well. Our next step was to look at the biomarkers to see if we could determine which patients were responding to treatment, based on tumor biology," said Carey, who is also an associate chair and professor of otolaryngology and pharmacology at the U-M Medical School.

The researchers found that 64 percent of the tumors were positive for high-risk strains of HPV. Almost all of the HPV-positive tumors responded to initial chemotherapy, and 78 percent of those patients survived with their organs intact. Of the HPV-negative patients, only four of 15 survived. In addition, patients with the EGFR marker had worse outcomes.

"The combination of markers was an important indicator. Patients whose tumors expressed high levels of EGFR did poorly. But those who had high EGFR and were also HPV-positive had some protection. Patients with high EGFR and low HPV fared the worst," Bhavna Kumar, a research laboratory specialist who was lead author on both papers, said in a prepared statement.

The U-M team also found that patients with low expression of protein called p53 and high expression of a protein called BCLXL also had poor outcomes.

More information

The American Cancer Society has more about oral and oropharyngeal cancers.



-- Robert Preidt



SOURCE: University of Michigan Health System, news release, May 12, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. A Better Tomorrow Becomes One of the First Rehabilitation Clinics in the Nation to Offer Financing for Its Drug, Alcohol and Gambling Treatment Programs
2. High-Tech Imaging No Better for Diagnosing Head/Neck Cancers
3. HPV linked to better survival in tonsil, tongue cancer, U-M study finds
4. Young Adults Using Alcohol, Drugs for Better Sex
5. Stroke Survivors Walk Better With Human Help
6. When statins arent enough: New trial drug points to better management of coronary heart disease
7. New Evidence Provides Clinicians With Better Tools to Help Smokers Quit
8. Medical research is essential to improving the economy and bettering lives
9. Simple Steps Lead to Better Blood Pressure Control
10. Improving Access to Safe Water, Sanitation, Hygiene Requires Better Decision-Making Tools, Finds Joint Wilson Center-Pacific Institute Report
11. New research on hearing health underscores the importance of better hearing and speech month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology: